CY-09 is a specific inhibitor of NLRP3 inflammasome and directly targets NLRP3. Its IC50 values for five major cytochrome P450 enzymes were 18.9, 8.18, >50, >50 and 26.0 µM, respectively.

 

Brand: BCM

 

Target: NOD-like Receptor (NLR); NOD

 

Signaling Pathways: Immunology/Inflammation; NF-κB

 

In Vitro: CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 and MCC950 specifically inhibit NLRP3 inflammasome activation and have no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization.

 

Solubiity: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

Isomeric SMILES: C1=CC(=CC(=C1)C(F)(F)F)CN2C(=O)C(=CC3=CC=C(C=C3)C(=O)O)SC2=S  

 

InChIKey: DJTINRHPPGAPLD-UHFFFAOYSA-N  

 

InChI: InChI=1S/C19H12F3NO3S2/c20-19(21,22)14-3-1-2-12(8-14)10-23-16(24)15(28-18(23)27)9-11-4-6-13(7-5-11)17(25)26/h1-9H,10H2,(H,25,26)

 

Attribute
[Chem Name]	4-[[4-oxo-2-sulfanylidene-3-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid
[Synonym]	CY-09
[CAS No.]	1073612-91-5
[MDL No.]	MFCD31619349
[Formula]	C19H12F3NO3S2
[Molecular]	423.43
[Form]	A crystalline solid
[Storage]	Sealed in dry, 2-8°C

Goods Tag